Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Mieko, Yanagisawa"'
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0203258 (2018)
PURPOSE:To compare the Esterman Disability Score (EDS) obtained with Goldmann perimetry (GP) testing and the Humphrey field analyzer (HFA) in low vision Japanese subjects. Subjects were also divided into groups by diagnosis to examine how disease inf
Externí odkaz:
https://doaj.org/article/af6f07a0d5a1442186b4d8ec26ab9fc9
Autor:
Ryo Asaoka, Hiroshi Murata, Mieko Yanagisawa, Yuri Fujino, Masato Matsuura, Tatsuya Inoue, Kenji Inoue, Junkichi Yamagami
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0184064 (2017)
To assess the thickness of the photoreceptor layer in the macular region in glaucomatous eyes.Humphrey 10-2 visual field (VF) testing was carried out and mean threshold (mTH) was calculated in 118 eyes from 118 patients with open angle glaucoma. Macu
Externí odkaz:
https://doaj.org/article/5b6a6a9e70be40799969ab5472fe3f05
Autor:
Masato Matsuura, Kazunori Hirasawa, Hiroshi Murata, Mieko Yanagisawa, Yoshitaka Nakao, Shunsuke Nakakura, Yoshiaki Kiuchi, Ryo Asaoka
Publikováno v:
PLoS ONE, Vol 11, Iss 8, p e0161742 (2016)
It is important to compare the results of Corneal Visualization Scheimpflug Technology instrument (CST) measurements and Reichert Ocular Response Analyzer (ORA) parameters. The purpose of the study was to investigate the association between CST measu
Externí odkaz:
https://doaj.org/article/36cdac481c104d8eb53ca8cf020cee81
Autor:
Hiroshi Murata, Ryo Asaoka, Mieko Yanagisawa, Takehiro Yamashita, Yuri Fujino, Masato Matsuura
Publikováno v:
Ophthalmology Glaucoma. 3:210-217
Purpose To investigate whether processing visual field (VF) measurements using a variational autoencoder (VAE) improves the structure–function relationship in glaucoma. Design Cross-sectional study. Participants The training data consisted of 82 43
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07287a02411fca9bffcee2aff7feba80
https://doi.org/10.1016/j.ogla.2020.01.001
https://doi.org/10.1016/j.ogla.2020.01.001
Autor:
SUGURU HARADA1, MIEKO YANAGISAWA1, SAORI KANEKO1, KEIGO YOROZU1, KANAME YAMAMOTO1, YOICHIRO MORIYA1, NAOKI HARADA1 haradanok@chugai-pharm.co.jp
Publikováno v:
Molecular & Clinical Oncology. Sep/Oct2015, Vol. 3 Issue 5, p987-994. 8p.
Autor:
Masato Matsuura, Hiroshi Murata, Yuri Fujino, Mieko Yanagisawa, Yoshitaka Nakao, Kana Tokumo, Shunsuke Nakakura, Yoshiaki Kiuchi, Ryo Asaoka
Publikováno v:
British Journal of Ophthalmology; Apr2020, Vol. 104 Issue 4, p563-568, 6p, 6 Charts, 2 Graphs
Autor:
Yuichi Asahina, Yohei Hashimoto, Hiroshi Murata, Ryo Obata, Ryo Asaoka, Tatsuya Inoue, Mieko Yanagisawa, Marie Kitano
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
Scientific Reports
Scientific Reports
The purpose of the current study was to investigate the structure-function relationship in patients with retinitis pigmentosa (RP) using optical coherence tomography and the MP-3 microperimeter. Visual field (VF) measurements were carried out using M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7318f3bde30513d62beae315a8299d77
http://link.springer.com/article/10.1038/s41598-017-16143-5
http://link.springer.com/article/10.1038/s41598-017-16143-5
Autor:
Mieko Yanagisawa, Koh Furugaki, Kaname Yamamoto, Masamichi Sugimoto, Mitsue Kurasawa, Keigo Yorozu, Nobuyuki Ishikura, Chinami Masuda, Toshiki Iwai
Publikováno v:
International Journal of Oncology
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating EGFR mutations (EGFR Mut+). However, almost all tumors eventually
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::079525187966d16cfb07b4c73bd20c43
https://doi.org/10.3892/ijo.2017.4036
https://doi.org/10.3892/ijo.2017.4036
Autor:
Mariko Noguchi-Sasaki, Mitsue Kurasawa, Kaname Yamamoto, Masamichi Sugimoto, Keigo Yorozu, Nobuyuki Ishikura, Toshiki Iwai, Mieko Yanagisawa
Publikováno v:
Anticancer Research. 37:623-630
Background Bevacizumab in combination with chemotherapeutics has shown significant survival benefit in clinical studies in patients with non-small cell lung cancer (NSCLC). Since bevacizumab was administered as standard treatment until disease progre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90baaa64b5c548738951d440c91d8e5d
https://doi.org/10.21873/anticanres.11356
https://doi.org/10.21873/anticanres.11356
Autor:
Sei Shu, Yasuhiro Kodera, Naoki Harada, Yoriko Yamashita-Kashima, Mieko Yanagisawa, Hayao Nakanishi, Yasushi Yoshimura
Publikováno v:
Anti-cancer drugs. 31(3)
Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 antibody drug, is the first-line therapy for human epidermal growth factor receptor 2-positive breast and gastric cancer. For breast cancer, the benefit of continuous treatment wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b72cfaf16677f7ecb8fecb2ef359c6b
https://pubmed.ncbi.nlm.nih.gov/31633500
https://pubmed.ncbi.nlm.nih.gov/31633500